Navigation Links
Major Clinical Study Supports NIPT As First Line Screening Test For All Pregnant Women
Date:8/13/2014

SAN CARLOS, Calif., Aug. 13, 2014 /PRNewswire/ -- Natera, Inc., a leader in non-invasive genetic testing, today announced a study to be published in the November issue of American Journal of Obstetrics and Gynecology, which shows that Panorama™ NIPT performs consistently well in all pregnant women, regardless of their prior risk level. This is the largest ever published study of clinical outcomes with NIPT, following more than 17,000 consecutive cases originally analyzed by Natera in mid-2013. It is also the second in a series of published studies showing strong test performance in low risk populations.

"This study supports the use of NIPT as a first line screening test for aneuploidy," said lead author Peer Dar, MD, Head of Fetal Medicine at Montefiore Medical Center in New York. "These results are consistent with recent NIPT guidelines published by the American College of Medical Genetics and Genomics (ACMG) that do not distinguish between high risk and low risk pregnancies, and which recommend NIPT in conjunction with first trimester ultrasound."

Key findings of this study:

  • Performance of the Panorama NIPT, determined previously in published case-controlled validation studies, has now been confirmed in a clinical setting with this study, the largest clinical outcomes study of NIPT to date. 
  • NIPT is already being adopted by some low-risk women and their healthcare providers, with 49% of the cases in this clinical study from women under 35 years of age.
  • The authors find that there are no concerns about performance of NIPT as a first line screen, and it will be accessibility and affordability that determine universal adoption.
  • The study highlighted an important performance metric: positive predictive value (PPV). Panorama's demonstrated PPV is significantly higher than traditional serum screening, by an order of magnitude. This should translate to a significant reduction in unnecessary invasive procedures and enhanced patient safety.

The results of this study, entitled "Clinical experience and follow-up with large scale single-nucleotide polymorphism-based non-invasive prenatal aneuploidy testing," by lead author Dr. Peer Dar and senior author, Dr. Peter Benn, are available online at www.ajog.org.

About Natera

Natera is a genetic testing company that designs targeted assays to analyze tiny quantities of DNA. The mission of the company is to help families diagnose and manage genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif., currently offering a host of preconception and prenatal genetic testing services primarily to OBGYN physicians and in-vitro fertilization centers. In 2013, the company launched Panorama™, a safe, simple test for pregnant women that screens for the most common chromosomal anomalies in a fetus as early as nine weeks of gestation. Tests developed by Natera have not been cleared or approved by the U.S. Food and Drug Administration (FDA). For more information, visit www.natera.com.

Contacts
GOLD PR for Natera
Shari Gold
714-251-0375
sgold@goldpr.com

Natera, Inc.
Mike Hromadik, 858-442-2215
mhromadik@natera.com


'/>"/>
SOURCE Natera, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD)
2. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
3. Tetra Discovery Partners Receives Major NIH Award To Develop New Alzheimers Drug
4. LIVE VIA SATELLITE: Physician Demonstrates New Medical Technology to Combat Back Pain without Major Surgery
5. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
6. Cardiosolutions, Inc. Gathers Major Investment from Sorin Group
7. PTC Therapeutics Announces Achievement of Major Milestone in Wellcome Trust BMI1 Collaboration
8. Misonix Exhibits at Major Worldwide Spine Conference
9. Rheumatoid Arthritis New Major Clinical Target After Mesoblast Obtains Positive Results in Inflammatory Arthritis
10. Aribex Reaches Major Milestone, Builds 10,000th NOMAD Handheld X-ray
11. Major Breakthrough in Hepatitis C Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017  AcelRx Pharmaceuticals, Inc. ... the development and commercialization of innovative therapies for ... the European Medicines Agency (EMA) has notified the ... mcg) Marketing Authorisation Application (MAA) has passed validation, ... is underway. The MAA for ARX-04 (known as ...
(Date:3/28/2017)... 2017 RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... Patent Office (JPO) for the composition of matter ... for the treatment or prevention of fibrotic disorders, ... proliferative retinopathy (Japanese Patent #: 6060071).  This patent ...
(Date:3/28/2017)... , March 28, 2017 ... to reach USD 8.0 billion by 2025, according to ... increasing incidence of infectious diseases and cancer is expected ... in disease diagnosis over the coming years. In addition, ... of autologous and allogenic stem cell therapy, due to ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... With less than 10,000 dermatologists in ... quality care can be limited while the desire to conquer breakouts and eliminate skincare ... care for every customer online, today released its inaugural survey on the State of ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Executives, Staff & ... money to for the Toys for Tots Literacy Campaign at their Semi-Annual Graduation and ... of $70 billion, the U.S. ranks at number 14 internationally in literacy. Statistically, a ...
(Date:3/28/2017)... Angeles, CA (PRWEB) , ... March 28, 2017 ... ... credential, which will be offered by the American Association of Integrative Medicine and ... presentations for healthcare providers at the AutismOne 2017 Conference in Colorado Springs. , ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Lice Treatment ... City March 13-16, was a busy spot this year. Liz Solovay and Adrian ... for preventing outbreaks among camp communities during the upcoming 2017 camping season. “Lice ...
(Date:3/28/2017)... Albertson, NY (PRWEB) , ... March 28, 2017 , ... Oily skin is a common ... with Advanced Dermatology has a lot to offer to the discussion of dealing ... good news is that there are many home remedies that can help remove the oily ...
Breaking Medicine News(10 mins):